Our mission is to develop Hepatology as a comprehensive discipline of medicine which can provide distinctly advanced and protocol based patient care, training and clinical and translational research. The Hepatology department at ILBS provides emergency and elective management to patients with liver, biliary and pancreatic diseases by a highly specialized and dedicated team of faculty, residents and supportive staff. With a rigorous academic program and constant monitoring and mentoring, the department is able to provide protocol and evidenced based care to an increasing number of difficult to treat patients.The department has initiated efforts to promote the study of Hepatobiliary Sciences as a super-specialty and initiated advanced training in the field of Hepatology and Transplant Hepatology.
Adult Hepatology Services: Diagnosis and treatment of alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), hepatitis B and C , A and E, auto-immune hepatitis, drug induced liver disease, and all causes of jaundice and liver failure are attended to. Gall stones and bile duct stones, pancreatic diseases, liver, gall bladder and GI cancers add to the specialized care. The following advanced care services are routinely offered through the hepatology department:
A). Liver Intensive Care:
The institute has established one of the finest liver intensive and critical care services with specialized rapid response teams. The LICU teams include specialists from Hepatology (Dr. Rakhi Maiwal I/c, Dr Rajan) and the Critical Care team(Dr. Lalita Gauri Mitra, Dr Prasant and Dr Vandana) round the clock. We provide care guided by a protocol-based treatment and rapid response by a multidisciplinary team ably supported by the nephrology, cardiology, pulmonology teams.
Acute G I Bleeds:
Patients with acute GI bleed are seen immediately in the emergency room and appropriate treatment is given immediately (Door to needle time <30 mins) including emergency endoscopy (door to scope time about 3 hours) throughout the year (24x7) which has resulted in keeping mortality to around 14% in patients with UGI bleed. Patients who fail the combination of endotherapy and vasoactive agents are taken up for portal pressure (HVPG) measurement and if suitable, considered for emergency TIPS procedure. There is a dedicated team available round the clock for all these procedures. New intervention of placing self-expanding metal stent, the Danis Ella Stent has greatly improved control of refractory variceal bleeding and patient survival. Probably the highest number of such stents are placed in the country, at the ILBS.
Hepatic coma: Hepatic encephalopathy is the occurrence of confusion, altered level of consciousness, and coma as a result of liver failure. It may ultimately lead to death.
A substantial increase in the patients admitted with hepatic coma occurred in the past one year. These patients are managed based on standard protocols and with our state of the art hepatic coma ICU functioning. New ammonia targeted approaches were introduced in with improved outcomes.
Acute Liver failure: Acute liver failure is the appearance of hepatic encephalopathy rapidly after jaundice, and indicates that the liver has sustained severe damage. Common causes include Hepatitis E, Hepatitis A, and drugs. ILBS has been involved in the treatment of ALF patients with a rapid response team working round the clock and with the availability of urgent liver transplantation the outlook of this disease has improved substantially. Specialized monitoring with Optic Nerve Sheath Diameter (ONSD) measurement and transcranial Doppler improved our diagnostic capabilities. Apart from this, we do high-volume plasma-exchange which removes a wide array of inflammatory toxins and cytokines in these patients and therefore facilitates recovery of the failing liver by providing an environment conducive for liver regeneration. High-volume plasma exchange in patients with acute liver failure is offered as a bridging therapy to spontaneous regeneration or liver transplantation. We routinely do plasma exchange for liver failure and have done this therapy in more than 100 patients in our intensive care unit, which is again probably the highest in the country. An early continuous renal replacement therapy (CRRT) in patients with acute liver failure is routinely done at our center. We havealso successfully offered a combination of these therapies in few patients with improved outcomes.
Acute on Chronic Liver failure[ACLF]: Liver failure can develop either acutely in the absence of any pre-existing liver disease [i.e. acute liver failure or ALF] or as acute on chronic liver failure (ACLF) which denotes a sudden deterioration of known or unknown chronic liver disease patient, which can be life threatening and requires intensive ICU care. This entity was first defined in India and ILBS has henceforth carried intensive research in this disease and developed effective treatments for this deadly condition. ILBS serves as the nodal center for the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) coordinated by Dr Ashok Chowdhary.
- At ILBS, there has been an ever-increasing referral of patients for management of these emergencies as shown in the figure below.
- Liver dialysis :Artificial liver support systemscan be non-cell based or cell-based systems. Several non-cell based extracorporeal liver support systems like hemodialysis, hemofiltration, plasma exchange, charcoal perfusion have been used in the past with a goal to remove the putative toxins and inflammatory cytokines to allow additional time for the liver to recover or as a bridge to liver transplantation. However, in all these protein bound toxins are removed to only a minor extent.
Single pass albumin dialysis (SPAD) , molecular absorbent and recirculation system (MARS) and recently, Prometheus (FPSA–fractional plasma separation and adsorption) which remove both water soluble and protein bound toxins have emerged as liver support therapies in patients with acute and acute on chronic liver failure. The Prometheus system which combines the FPSA method with high-ï¬ÂÂÂuxhemo-dialysis (of the blood) in an extracorporeal detoxiï¬ÂÂÂcation system.
These newer developing therapies have demonstrated benefits in biochemical parameters, systemic hemodynamics, hepatic encephalopathy and also renal functions but are expensive and enough data is available on safety of these devices. They can be used as a bridge for spontaneous recovery or transplantation in patients with ALF. In patients with acute on chronic liver failure (ACLF) with hepatorenal syndrome or hepatic encephalopathy (without contraindications for transplantation) in order to improve their chances to be listed and transplanted
We are also the first center in the country to have facility of doing both MARS and Prometheus. These therapies could be effective in improving hepatic encephalopathy and renal failure and provide a potential support for multiorgan failure in patients with liver failure awaiting liver transplantation. In addition to this, wherein these therapies are contraindicated due to severe coagulopathy plasma-exchange is effectively done in these patients as a bridging therapy to liver transplantation. Plasma-exchange has been shown to ameliorate systemic inflammation, prevent organ failures and as a bridge to liver transplantation in patients with ACLF. These therapies have also been effectively offered to patients with Drug induced liver injury, hemophagocyticlymphohistiocytic syndrome, intractable pruritus secondary to intrahepatic cholestasis and autoimmune hepatitis who have failed steroid therapy. We have the largest experience in the country on artificial liver support therapies in context of liver failure uptill now these therapies have been offered to over 50 patients.
We at ILBS are also trying to develop our "bioartificial liver" with extracorporeal bioreactors containing hepatocytes which can provide additional synthetic and biotransformatory liver functions, which may be more effective than completely artificial systems like Prometheus which provide excretory capacity alone.
B). Viral Hepatitis (A,B,C,E) and Hepatocellular Carcinoma Services:
- Hepatitis B and C are common causes of chronic liver disease in India and nearly 45 and 12 million people are estimated to be infected with these viruses in India respectively. They are also the common cause of cirrhosis and liver cancer
C). Alcoholic liver disease:
At ILBS, alcoholic liver disease is the most common diagnosis requiring admission. ALD constitutes more than 40% of our in-patients and 2/3rds of our patients with acute-on-chronic liver failure. We have protocol based treatments available for alcoholic hepatitis patients led by Dr Shasthr. We have recently shown survival benefits in patients not responding to the standard of care with growth factors and those not eligible for standard of care with use of new protocols using fecal microbiota transplantation (FMT) from a healthy donor. We further are trying to standardize protocols, which could in future become the standard of care in the management of severe alcoholic hepatitis patients.
D)Liver stiffness and fat measurement :
Early diagnosis and intervention can lead to a substantial reduction in morbidity and mortality from all conditions that lead to cirrhosis. Liver stiffness is important for evaluating the stage of liver fibrosis. The transient elastograpy (FibroScan®) technique measures the liver stiffness. This is used to quantify hepatic fibrosis in a totally non-invasive and painless manner, with no contra-indications for the patients. FibroScan allows accurate assessment of liver fibrosis resulting from all chronic pathologies that cause damage to the liver, including metabolic syndrome and non-alcoholic fatty liver disease, chronic viral hepatitis and excess alcohol intake. In the early stages of liver disease tests and conventional ultrasound have a poor predictive value in assessing fibrosis. Liver stiffness measurement is the ideal diagnostic tool to accurately identify liver fibrosis and fat quantification and is being increasingly used at ILBS.
E). Endoscopy Services:
The department of hepatology providesmost comprehensive endoscopic services- both diagnostic and therapeutic. Our spacious endoscopy unit has seven fully equipped rooms- two for gastroscopy, one for colonoscopy, one each for endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS), cholangioscopy, Intraductal ultrasound, one balloon enteroscopy room, and one room for extra-corporeal shock wave lithotripsy (ESWL). Experienced endoscopists, nurses and anesthesiologists receive all patients in a spacious day care reception area, where they are assessed pre-procedure. All elective endoscopic procedures at ILBS are carried out with tailored sedation provided by consultant anesthesiologists. Patients undergoing prolonged procedures, and high-risk patients are administered general anesthesia with elective endotracheal intubation and ventilation. After the procedures, patients are monitored in a segregated post-procedure observation area with full monitoring facilities and privacy. The services are efficiently supervised by a Resident Medical Officer, Dr. Sakshi.
We have a round–the-clock gastrointestinal bleeding service and a round the clock, GI Bleed unit with consultant endoscopists on 24-hour call. The highlights of the gastrointestinal bleeding service include a fully equipped ambulance with on-site resuscitation facilities, to triage at admission, and all endoscopic therapeutic procedures. These include variceal banding and injection, glue injection, thermal coagulation, argon plasma coagulation (APC), and hemostatic metallic stent implantation, Dennis Ela stent placement. We take pride in having the shortest ‘door to endoscopy’ time, which is unrivalled by any other hospital.
Our interventional radiology services work in tandem, and provide salvage angioembolization , TIPS and BRTO services for difficult to control or inaccessible bleeding sources. ILBS has one of the largest experiences in emergency TIPS stent placement. All patients with gastrointestinal bleeding are managed in an intensive care setting.
We provide comprehensive pancreato-biliary endoscopy services. These include Extra-corporeal shock wave lithotripsy (ESWL) to fragment pancreatic and bile duct stones, therapeutic ERCP, and diagnostic and therapeutic endoscopic ultrasound (EUS) procedures. We have the experience of one of the highest EUS procedures done in the country. All our EUS procedures are done under anesthesia, providing unsurpassed patient comfort and safety. We are the one of the center to have dedicated on-site cytopathology services, with EUS sampling adequacy rates exceeding 97%. We are routinely doing intra-gastric balloon (IGB) placements for management of patients with morbid obesity with perceivable results. Forty-four IGB placements were done in 2018 alone.
We have the second generation cholangioscopy system and intra-ductal ultrasound systems for difficult biliary pathologies. We also have the holmium laser fiber system for cholangioscopic treatment of difficult bile duct stones. We are also introducing magnification and image-enhanced endoscopy, contrast-enhanced EUS, EUS-elastography, miniprobe sonography, and in-vivo histology by using probe-based laser confocal system. We are setting up a state-of-the art data archiving and management system, for audit and research purposes. Our endoscopy informatics system is integrated with the hospital PACS system.
The goal of endoscopy services at ILBS is amalgamation of cutting edge technology with a humane touch. We strive to make endoscopy a pleasant experience for all patients, with attention to small details including lockers for personal belongings, clean clothes and towels, clean toilet facilities, and post-procedure discussion of the findings. Our smiling and pleasant staff is trained to put patient apprehensions at ease.
There is ever increasing load of Endoscopic Procedures through the years as shown in figures below.
Abbreviations: Capsule E: Capsule endoscopy; SVE: Side-viewing endoscopy, EUS FNAC: Endoscopic ultrasound guided fine needle aspiration
Abbreviations: EVL: Endoscopic variceal ligation; APC: Argon plasma laser coagulation; HP: Heater probe; Glue: Glue injection; ERCP: Endoscopic retrograde chlolangiopancreatography, Others include Extra-corporeal shock wave lithotrypsy, Polypectomy and Achalasia Dilatation
F). Hepatic Hemodynamic Laboratory:
The hepatic hemodynamic laboratory is the backbone of Hepatology services. Under the supervision of Dr. Ankur Jindal, it provides detailed insight into the liver pressure which determines the outcome of patients with liver disease. Measurement of the hepatic venous pressure gradient (HVPG) is currently the best available method to evaluate the presence and severity of portal hypertension. Other unique features of this laboratory are accurate measurement of Pulmonary pressures, which is helpful in accurate diagnosis of porto-pulmonary hypertension and measurement of cardiac output; and simultaneous liver biopsy sampling even in patients with ascites and liver disease enabling accurate diagnosis and severity of liver disease.
The management of patients of liver disease is based on reduction in complications (such as variceal bleed, development of ascites and renal failure) and an opportunity to regenerate the liver. All this is done in a protocol and outcome based manner at the ILBS. Normal HVPG is <5 mm Hg and an HVPG >10 mm Hg (termed ‘clinically significant portal hypertension’ or CSPH) predicts the development of various complications of cirrhosis. Importantly, HVPG above 12 mmHg is the threshold level for variceal rupture and a reduction of HVPG to <12 mmHg or by 20% of baseline considerably reduces the risk of bleeding, mortality and other complications of cirrhosis, such as spontaneous bacterial peritonitis and hepatic encephalopathy. We are currently running protocols on HVPG response based approaches on primary prophylaxis of variceal bleed in cirrhotics and HVPG based approach for managing acute variceal bleed. Sequential HVPG measurements are helpful to optimize drug therapy or switch to another form of therapy.
The main advantages of the hepatic vein catheterization technique are its simplicity, reproducibility, and safety. Since its result has important implications, the appropriate and correct measurement of HVPG is an important issue both in research and clinical practice.
Because of its relatively invasive nature and domain skills, this facility is available in very few centers in the world. We at ILBS regularly perform this procedure taking due precautions that all the steps are performed with precision and patient safety.
G). Clinical Nutrition
Over the last six years since its inception the Department of Clinical Nutrition is committed to patient care, along with nutrition education and research in collaboration with all the other departments at ILBS. Services for a detailed assessment of the nutritional status using a bioelectrical impedance analysis and anthropometry are provided by the department. Besides this the indirect calorimeter is the new research artillery in the department’s arsenal. More than 300 liver disease patients with NAFLD and obesity are in regular follow-up with the “Liver Nutrition Clinic” in the OPD. Several nutrition related research projects are also underway for the fulfillment of the degree of PhD, DM, MCh and DNB students. The department is also actively involved in the teaching activities scheduled for its residents, nursing students and faculty.
Courses Offered : DCC and Ph.D. in clinical nutrition
Three bright students are presently pursuing PhD in the department.
Ms. Harshita Tripathi
Oral presentation at APASL Liver Meeting, 14-18th March 2018, New Delhi, India. "Aggressive Nutrition Therapy Significantly improves 28 Day Survival in Critically Ill Cirrhotics with high Nutrition risk as Assessed by NUTRIC Score"
Dr. Varsha Shasthry:
- Poster presentation at AASLD Liver Meeting, 2018, 9-13th November 2018, San Francisco, CA, USA. "Visceral Adiposity Fans the Flame of Mortality in Sarcopenic Patients with Liver Cirrhosis"
- Poster presentation at ISGCON 2018, 28 Nov-1 Dec 2018, Kochi, Kerala, “Presence of Visceral Adiposity Fans the Flame of Mortality Amongst Sarcopenic Patients with Liver Cirrhosis”.
I). Liver regeneration and stem cell therapy
Only about 2-5% of patients, with advanced cirrhosis are able to get liver transplant. Lack of a donor, very advanced stage, financial and social issues are the major limitations. There is therefore an urgent need to provide alternative methods of maintaining and improving liver functions. In this regard, emerging science of regenerative medicine is considered an effective alternative therapeutic approach that can effectively manage the necro-inflammatory death of hepatocytes, potentiate immunomodulation and thus promote native liver regeneration and repair.
In cirrhosis as well as in ACLF, the supportive signals for liver to regenerate get severely compromised and liver microenvironment becomes impermissible for regenerating cells, resulting in reduced liver mass and function. Potential of stem cells to differentiate into multiple cell lineages raises the exciting possibility that these cells can be used in repair and liver regeneration, when resident stem cells are not sufficient for the regeneration of a failing liver During liver regeneration, bone marrow-derived hematopoietic stem cells (HSC) may mobilize to the liver and, together with hepatocytes and intrahepatic stem cells, contribute to the proliferation of liver cells. Mechanistically, the approaches attempting to augment bone marrow stem cell can be divided into two main categories: enhancement of the endogenous stem cell response and augmentation of cell-based therapies by transplantation. The field of liver regeneration is led by Dr. Rajan, Dr Anupam and Dr. Chhagan Bihari at ILBS. The trio under the guidance of Prof Shiv Sarin has done many seminal works in the field of regenerativemedicine. Growth factor administration was shown to be a simple and novel method of mobilizing BMSCs. We at ILBS, have successfully used growth factors like granulocyte colony stimulating factor (G-CSF) and erythropoietin to mobilize stem cells to the periphery in patients with advanced cirrhosis and ACLF and shown survival benefit in a subgroup of these patients. It was shown that there is a senescence of bone marrow in patients with advanced cirrhosis. Patients with early decompensated cirrhosis (MELD<16) and those with a healthy cellular baseline BM respond better to growth factor therapy. Based on these concepts, growth factor administration after proper selection of patients is now a part of routine treatment of CLD patients at ILBS, particularly in those not having any option of transplant.
Several laboratorial and clinical studies showed that various cells, including mature hepatocytes in adult liver (adult HCs), fetal liver cells (FLCs), hepatic stem/progenitor cells (HSPCs), mesenchymal stromal cells (MSCs), are the potential sources of cell based therapies for liver failure, including acute on chronic liver failure as well as acute liver failure. Thus, our future endeavour in this field of regenerative hepatology includes novel interventional approaches, including transplant of bone marrow cells and/ or exosome infusion from allogeneic healthy bone marrow in the management of cirrhosis. Also we are studying the role of MSC transplant in management of ACLF patients. Utilization of macrophage therapy and/or CSF1 is also in our pipeline projects. Recently, in collaboration with IIT Kanpur, we have worked on a bio-artificial Liver (BAL) device tomeet the metabolic demands of body. We have also worked on an emerging new approach of using decellularized liver for this purpose. We aim for a future in which no patient with liver disease dies due to failure to get liver transplant.
With this aim and with a strive to become a centre of Excellence for Hepatic Regenerative Therapies, ILBS has received grant from Department of Science and Technology (DST) for a project titled “Development Of Non-Transplant Therapeutic Strategies For Advanced Liver Diseases”; phase 1 of which is ongoing.
J). Transplant Hepatology
Liver disease either acute or chronic when failed to improve with medical management, liver transplant is the therapy. Acute liver failure or acute on chronic liver failure require emergent transplant where as end stage liver disease needs a prompt and timing decision for the same. Our transplant team led by Prof Shiv K Sarin and monitored by Dr Ashok Choudhury. The students get unique opportunity to be exposed to this highly specialized care during their posting that includes pre transplant evaluation of donor and recipient, pre transplant optimization and post transplant follow up. ILBS is the only public sector hospital in Govt setting to have a successful transplant programme with 101, 93, 87 and 99 liver transplant per year in 2015, 2016, 2017 and 2018 respectively. This is possible due to able lead by Transplant Surgery team by Prof Viniyendra Pamecha and Dr Senthil Kumar. Cadaver transplant, as well as mantainace of transplant waiting list in strict accordance of the NOTTO Guideline is a great achievement where nearly 250 patients were routinely followed by Transplant hepatology team and record maintained by Transplant Coordination department led by Mrs Vibhuti-a passionate and dedicated person. The immediate post transplant care is offered by surgical, medical and anaesthesia resident doctors, nursing staff; 24x7 phone support (transplant SR on call mobile no-+91 7835055601), whatsapp support (mobile no-+91 9650951049), email (email@example.com) and a dedicated post-transplant ward supervised by Dr Ashok Choudhury. Post transplant complications are uncommon; and if they occur, they are managed well. These include progressive multifocal leukoencephalopathy (PML), late onset antibody mediated rejection (AMR) in ABO compatible transplant, Graft Versus Host Disease (GVHD), post-transplant lymphoproliferative disease (PTLD), post LT malignancies. An algorithmic approach to post-LT Biliary complications is undertaken by ERCP or PTBD. International (7) and national (15) fellows had been trained on transplant hepatology till date. Training of manpower (Fellowship on transplant hepatology, transplant critical care and transplant immunology, transplant nursing and co-ordination), academic excellence, translational research (noninvasive methods for early detection of graft rejection, cell based therapy for steroid resistant rejection and immunoscan, etc.) and strategies to increase organ donation awareness, organ retrieval and promotion of cadaver transplant are in pipeline for the future.
K). Protocol based treatment
For patients with acute on chronic liver failure (ACLF), portal hypertension and variceal bleeding, hepatitis B and C and non-alcoholic steatohepatitis (Fatty liver disease), the department has been able to standardize the treatment protocols.
L). Patient support services
For patients with hepatitis B and C, and portal hypertension, highly skilled and trained nurses are now available to monitor the patient treatment and outcomes.
A dedicated 24 hour toll free no.1-800-11-5354 has been designated as “Liver Help Line” for the benefit of patient and their relatives. Questions related to liver diseases are answered round the clock by hospital emergency staff at this telephone number. Liver helpline also functions as telephone triage service and depending upon the urgency it helps patients and their relatives directed towards seeking appropriate level of health care.
Training and CME
Regular training programs are conducted for BLS and ACLS certification. Resident doctors, casualty medical officers, nurses and technicians have regular access to high quality clinical CMEs at the institute.
|Emergency care services||7232||8222|
|Upper GI Endoscopy diagnostic||8313||8488|
|Regeneration and stem cell therapy||65||71|
|Body Composition Analysis||914||1443|
New services & facilities
Fecal (Stool) Microbiota Transplantation (FMT) Unit
The human microbiota consists of trillions of microorganisms found in the human body, with the majority of organisms colonizing the gut from mouth to colon. A large number of diverse microbial species reside in the distal gastrointestinal tract, and gut microbiota dysbiosis (imbalances in the composition and function of these intestinal microbes) and excessive release of gut microbial products into the portal circulation has been implicated to have pivotal role in the development and progression of many of the liver diseases and their complications, most importantly - non-alcoholic steatohepatitis, alcoholic liver disease, alcoholic hepatitis, hepatic encephalopathy, sepsis in liver diseases etc. Globally, many efforts are currently concentrated on exploring potential possibility of exploiting the gut microbiome in the management of liver diseases. An improved understanding will fuel the conception and realization of novel therapeutic and preventive strategies. The gut microbiome (interaction between different microbes and their genes) contains 100 times as many genes as the whole human genome and hence is an important and less explored area in medicine. Fecal (stool) microbiota transplantation (FMT) involves acquiring healthy microbes from a related donor and then instilling these into the GI tract of the diseased individual. At ILBS, FMT is being used as a novel method in the treatment of severe alcoholic hepatitis, which otherwise is lethal nearly half, with limiting targetted therapeutic options other than liver transplantation. Earlier, we at ILBS have utilized FMT for the treatment of steroid ineligible responsive alcoholic hepatitis wherein the response has been encouraging with an improved survival. Lately we have initiated a trial where we intend to compare the effectiveness of FMT in comparison to steroids (which is the only approved option with its own side effects and limitations) in patients of severe alcoholic hepatitis. Up till now, more than 90 patients have been enrolled in the trial. The work in the FMT lab is co-ordinated by Dr Shasthry, with the help of Dr Vikas Khillan and Dr S K Sarin.
Due to increased demand of day care services like large volume paracenteses, pleural fluid paracentesis (in hepatic hydrothorax) albumin infusions etc… we have opened a new albumin day care in Phase-2, first floor since June 2017. This ward has 15 operational beds of which 5 are dedicated for USG guided ascites tapping. The ward offers facilities to the needy patients in three shifts, with prior appointment. Dedicated telephone extension has been allocated to take appointments to avail the day care facilities- [Albumin Day Care Phone No. 011-46300000-Extn: 22152]The ward is catering over 500-600 patients a month since its inception. 3 shifts are being run where about 15-20 patients per shift undergo paracentesis and receive albumin infusion. In the year 2018, this day care has served more than 7,000 patients. The service is supervised by Dr Shasthry S.M and Dr. Imran.
- 27th Annual liver meet of the 'Asia Pacific Association for Liver Disease' March 14-18, 2018 was organized by the Institute of Liver and Biliary Sciences in New Delhi and was attended by nearly 3,500 delegates.
- Indo French meeting- on recent advances in molecular analysis of liver diseases MARCH 19th, 2018
- World Hepatitis Day : 28 July, 2018
- 4th AARC consensus meeting, October 1-2, 2018
- 27thHepatitis Awareness Day: 4 Dec, 2018
|Names of the Course||Candidates Admitted||Candidates Passed|
|DM Hepatology: Admitted in 2018:||Dr. Satender Pal Singh, Dr. Pinakee Sunder Kar, Dr. Ajay Kumar Mishra, Dr. Abhijeet Ranjan||Dr. Shakti Prasad Choudhury, Dr. Anand V Kulkarni, Dr. Abhinav Verma, Dr. Juned Ahmad|
Asia Pacific Association For Study Of Liver (Apasl) School Of Hepatology :
APASL School of Hepatology at ILBS, New Delhi, India offers a continuous teaching and training covering diverse aspects in the field of Hepatology. A combination of lectures, clinical case-based discussions, and training in various procedures, with intense interaction and time for personal discussion and personalized training. The major goal is to induct and train new generation of hepatologists. By inviting young fellows or faculty enrolled in hepatology-oriented departments throughout Asia, who want to be exposed to the newest trends in hepatology, the APASL School of Hepatology would achieve the unmet needs of the region.
Till now ILBS has trained 25 trainees in Hepatology through the APASL School of Hepatology.
World Gastroenterology Organization (Wgo) New Delhi Training Center:
The New Delhi Training Center at ILBS was inaugurated in New Delhi, India on April 26, 2015 as a WGO Training Center. The New Delhi Training Center mission is to to induct and train new generation of Hepatologists, provide continuous teaching and hands on training covering diverse aspects in the field of Hepatology and focus on the development of academic physicians in hepatology who will excel and become leaders in the field. The first batch of trainees will start their training in 2019.
Other Training Opportunities In Department Of Hepatology:
Besides APASL School of Hepatology and WGO Training center, ILBS also offers individualized hands on training courses according to needs of the candidates.
Department Research activities : Department is actively involved in clinical as well as basic research in varied areas such as Portal hypertension and its complications, Viral hepatitis, Alcoholic liver diseases, Non alcoholic fatty liver disease, Acute Liver Failure, Acute on Chronic Liver Failure, Kidney injury in Liver diseases, Liver regeneration, Liver transplant. In the year 2018, due to increased burden and challenges in the field of hepatocellular carcinoma, the department has started work in immunotargeting and immunotherapy for HCC.
Department of hepatology has given important contributions to developing guidelines for treatment of various hepatological diseases like APASL guidelines for hepatitis B, hepatitis C, liver fibrosis, hepatocellular carcinoma, variceal bleed, non-cirrhotic portal hypertension, International ascites club guidelines for AKI in cirrhotics. Department is also involved in developing novel therapies for liver diseases like regeneration therapies of liver using growth factors, fecal microbiota therapy for severe alcoholic hepatitis, newer biomarkers for liver cancer, AKI etc.
APASL ACLF Research Consortium (AARC)- Largest Multinational Research Project in Liver Diseases across Asia
Liver disease is a major health burden. To have a reserchcollboration and exchange of science and knwoledge in general and “Acute on Chronic Liver Failure (ACLF)” in particular , the APASL-ACLF Research Consortium (AARC) was initiated by Asia Pacific Association for Study of Liver (APASL) under dynamic leadership of Prof Shiv Kumar Sarin. Started in early 2005 and upscaled in 2008 with a small group of like minded investigators developed the first consensus on ACLF, which was published in 2009. Subsequently, it is the contribution by all serious investigators across Asia working in this field, and unparalleled support from the APASL to hold the regular updates and consensus meetings and finally publishing our revised ACLF guidelines in 2014. Today, AARC has become one of the largest databases having more than 5400 cases from Asia (50 centre, 16 countries).
The vision of AARC is to develop a collaboration of likeminded clinicians, researchers to work on ACLF, formulate the practice guideline, follow the evidence based treatment and also to make the unified approach to this disease across the globe.
Facilities and Research Work
Protocols and Collaborative Research : AARC is actively doing the multicentric prospective reserch on various aspects of ACLF. Centres from Korea, China, Pakistan, Bangladesh as well as India doing multiple projects.
Publications : Till now 6 manuscripts under AARC have been published. A strict manuscript policy has encouraged more and more publications in pipeline in leading journals like-hepatology, hepatology international, liver international and many others. AARC has shown its interntional presence with good number of research papers as abstarct in most of the liver conferences including-AASLD, EASL, APASL, ILTS and others.
Sample Collection : Blood samples are collected of patients who give their consent for the same. It is proposed to keep them stored at -80 C.Nodal centre has facility for sample storage and thus encourages all the members to ship the samples to the centre for proper storage, which is readily available for future use by the respective centres.
The AARC nodal centre conducts monthly video conference in the Zoom cnference paltform with nodal centre being the host and other centre do join regularly to discuss the protocols, conflicts and scentific discussions. Till now AARC conducted 50 such confrences which is sheduled for the third Friday of everymonth.
The Journey so far :
- 2012: The Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 gave its first consensus report on acute-on-chronic liver failure (ACLF) in 2009 and formed APASL ACLF Research Consortium (AARC) in 2012 in Dhaka.
- 2014: 3rd APASL ACLF (AARC) meeting and revision of Consensus was done in a 2-day meeting conducted in February 2014 at New Delhi.
- 2015: 4th APASL ACLF (AARC) working party meeting, Istanbul, March 2015.
- 2016: 5th APASL ACLF Research Consortium (AARC) at Tokyo, February 2016.
- 2017: 6th APASL ACLF Research Consortium (AARC) at Shanghai, February 2017.
- 2018: 7th APASL ACLF Research Consortium (AARC) at New Delhi, March 2018.
- 2018: 4th APASL ACLF Consensus Revision (AARC-4) at New Delhi, October 2018.
ILBS hosted the 4th AARC Consensus Update, which was attended by 120 national and international experts from all countries across the Asia and a robust Pan Asia data of 5400 patients of ACLF was analyzed and consensus was updated. The work was co-ordinated by Dr Irene and Priyanka, under the supervision of Dr Ashok and guidance of Dr Sarin.
Dr. Shakti Prasad Received 'Young investigator award and best abstract award’ for presenting his work on ‘Continuous infusion of terlipressin is more effective and safe than bolus administration in HVPG reduction in patients with acute esophageal variceal bleed- A randomised controlled trial’ at AASLD , USA.
Dr. Anand Kulkarni
APASL transplant quiz winner(first prize) with honorary membership in march APASL 2018 plus cash prize (10,000)
Visiting faculty to the department in 2018
|Name||Institution/strong>||Date of Visit|
|Dr. Yvan J. Hutin`||Strategic Information, Global Hepatitis Programme WHO Headquarters, Avenue Appia, Geneva 1211, Switzerland||13-03-2018|
|Dr. Ahmet Gurakar||Medical Director, Liver Transplant Associate Professor of Medicine Division of Gastroenterology and Hepatology Johns Hopkins University School of Medicine||16-03-2018|
|Dr. Hemant Shah||Clinical Practice Director, Francis Family Liver Clinic
Assistant Professor, University of Toronto
|Dr. Ronald J. Sokol,||Professor and Vice Chair of Pediatrics Director, Colorado Clinical and Translational Sciences Institute Assistant Vice Chancellor for Clinical and Translational Science, Univ. of Colorado Denver Chief, Section of Pediatric Gastroenterology, Hepatology and Nutrition and the Digestive Health Institute University of Colorado School of Medicine Children's Hospital Colorado, Box B290 13123 E. 16th Ave. Aurora, Colorado 80045, U.S.A.||17-03-2018|
|Dr. Richard Thompson||Professor of Molecular Hepatology, Honorary Consultant Paediatric Hepatologist King’s College, London||17-03-2018|
|Dr. Nanda Kerkar,||Professor of Pediatrics University of Rochester Medical Center Director Pediatric Liver disease and Liver Transplant Program Golisano Children’s Hospital 601 Elmwood Avenue, Box 667 Rochester, NY 14642|
|Dr. Roshni Vara||Consultant in Paediatric Inherited Metabolic Disease Evelina Children’s Hospital St Thomas’ Hospital Westminster Bridge Road London SE1 7EH||17-03-2018|
|Dr. TamirMiloh||Baylor College of Medicine, Houston, Texas||17-03-2018|
|Dr. Olivier Soubrane||Hospital Beaujon, Paris France||20-03-2018|
|Dr. Chandan Guha,||Professor, Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, USA||24-03-2018|
|Prof. Richard L. Ehman||Professor of Radiology, Mayo Clinic, Rochester, Minnesota||27-03-2018|
|Dr. Gonzalo Sapisochin||Assistant Professor of Surgery Abdominal Transplant and HPB Surgical Oncology University Health Network University of Toronto||08-04-2018|
|Dr. David Grant||Professor General Surgery University Health Network University of Toronto||08-04-2018|
|Dr. Elena Ivanova||Senior Scientific Officer HCV programme FIND Headquarters Geneva, Switzerland||01-06-2018|
|Dr. Beatrice Vetter||Scientific Officer HCV Program||01-06-2018|
|Dr. Richard Moreau||Vice-Chairman, Centre de Recherche sur l’Inflammation CRI,Consultant in Hepatology, Liver Unit, Beaujon Hospital , Assistance PubliqueHôpitaux de Paris (APHP), Clichy, France and Adjunct Professor ILBS.||04-07-2018 - 07-07-2018|
|Dr. Geoffrey Dusheiko||Emeritus Professor of Medicine University College London Medical School Kings College Hospital||02-08-2018|
|Dr. Diana A Payawal||Cardinal Santos Medical Center, Manila, Philippines,||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Cosmas Rinaldi Lesmana||Digestive Disease & Endoscopy Center, Medistra Hospital, Indonesia||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Dong Joon Kim||Hallym University College of Medicine, South Korea||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Saeed Hamid||Aga Khan University Hospital, Karachi, Pakistan||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Guan Huei Lee||Yong Loo Lin School of Medicine, National University of Singapore||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Eileen L Yoon||SanggyePaik Hospital, Inje University College of Medicine, Seoul, Korea||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Jin Mo Yang||Hallym University College of Medicine, South Korea||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. A KadirDokmeci||Ankara University School of Medicine, Turkey||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Qin Ning||Tongji Hospital, Tongji Medical College||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Mohd. Fazal Karim||Sir Salimullah Medical College, Mitford Hospital, Bangladesh||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Atsushi Tanaka,||Teikyo University School of Medicine, Tokyo, Japan||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Salimur Rahman||Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. HasmikGhazinian||Nork Clinical Hospital of Infectious Disease, Armenia||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Soek Siam Tan||Selayang Hospital, Kepong, Malaysia||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Mamun Al Mahtab||Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Sombat Treeprasertsuk||Chulalongkorn University, Bangkok, Thailand||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. SoeThihaMaung||Win Sammering Specialist Clinic and Medical Check-up Centre, Myanmar||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Satoshi Mochida,||Faculty of Medicine, Saitama Medical University, Japan||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Do Seon Song||Hallym University College of Medicine||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Hai Li||Ren Ji Hospital, School of Medicine,Shanghai Jiao Tong University,Shanghai, China||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Jinhua Hu,||302 Millitary Hospital, Beijing, China||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. RinoGani||University of Indonesia, Indonesia||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Xiaolong Qi||Hepatic Hemodynamic Lab, Nanfang Hospital, Southern Medical University, Guangzhou, China||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Wei Ting Chen||Linkou Chang Gung Memorial hospital, Taiwan||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. KhinMaung Win||University of Medicine 1, Yangon,Ministry of Health and Sports, Myanmar||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Yu Chen||Beijing You’an Hospital; Translational Hepatology Institute, China||Participated in 4th AARC Consensus update on October 1-2, 2018 at ILBS|
|Dr. Klaus Goerlinger||Medical Director of Tem Innovations, Munich, Germany||19-11-2018|
|Dr. Honey V. Reddi||Clinical Laboratory Director, Farmington, CT, USA||20-11-2018|
|Dr.RajanikanthVadigepalli||Professor and Vice Chair of Research Daniel Baugh Institute for Functional Genomics/Computational Biology Department of Pathology, Anatomy and Cell Biology Jefferson (Philadelphia University + Thomas Jefferson University)||13-12-2018-14-12-2018|
|Dr. Adrian Reuben||Professor of Medicine Emeritus Division of Gastroenterology and Hepatology Medical University of South Carolina||18-12-2018 to 19-12-2018|
|Dr. Richard Moreau||Vice-Chairman, Centre de Recherche sur l’Inflammation CRI,Consultant in Hepatology, Liver Unit, Beaujon Hospital , Assistance PubliqueHôpitaux de Paris (APHP), Clichy, France and Adjunct Professor ILBS||19-12-2018 to 22-12-2018|